Abstract 4399
Background
A recent analysis of 12 trials in first line showed similar outcomes for elder vs younger patients. Nevertheless these results might be due to a selection bias. The aim of our study was to assess whether elder patients (pts) (>60 years) had the same outcomes than younger (<60 years) in an unselected population of STS stage I-IV.
Methods
A retrospective analysis of pts diagnosed with STS stages I-IV at two institutions between 2000 and 2015 was performed. GIST and other indolent STS such us low-grade stromal sarcoma tumors, cutaneous Kaposi Sarcoma, Desmoid tumors and dermatofibrosarcoma protuberans were excluded. Demographic, clinical and pathological variables were obtained from the medical charts. Overall survival (OS) was calculated according to the date of death by any cause or lost of follow-up.
Results
115 pts, men/women 59/56 median age of 54.6 years (16.6-82.62) were included. 71 pts (61.7%) were <60 years (younger) and 44 (38.3%) were >60 years (older). Most frequent subtypes were liposarcoma (16.5%), leiomyosarcoma (14.8%) and undifferentiated sarcoma (9,6%). Most frequent sites were lower extremity (27.8%) , retroperitoneum (13.9%) and thorax (13.0%). TNM Stage (or FIGO in endometrial origin) were stage I-II (53%), III (38%) and IV (19%). 98 pts were operated of the primary tumor (Resection was R0 in 53, R1 in 30 and R2 in 4, in 11 data was missed). 37 pts (32.2%) received anthracyclines in any line (31 in younger and 6 in older pts). 68 pts (59.1%) had a local or systemic relapse. 53 pts died (46.1%). There were no differences by age group on stage, grade and radicality of surgery (chi squares p = 0.52, 0.48 and 0.47 respectively). Nevertheless elder patients were less likely to receive anthracycline-based therapy (RR 0.33 95%IC 0.16-0.72, p = 0.001). Grade and stage were significant prognostic factors for OS: median OS 104.4 m for Stage I-III vs 14.7 m Stage IV, p < 0.0001 and 146 m for low (grade 1-2) vs 49.1 m for high grade (grade 3) p = 0.0025, respectively. Age group had no effect on median OS (74.4 months for younger and 78.9 months for older log Rank p = 0.13).
Conclusions
Despite significant undertreatment with anthracycline regimens, elderly patients do not have worse survival outcomes in this exploratory analysis of an unselected population.
Clinical trial identification
Legal entity responsible for the study
Hospital Clinico Universitario de Valencia. INCLIVA.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract